Will expand Phase II trial of melanoma tumor vaccine derived from cultured tumor cell lines and the firm's immunostimulant Detox from 70 patients to 270 patients at five new study sites. FDA clearance of the firm's Hamilton, Montana facility for the production of its cancer vaccine made the additional studies possible. The vaccine had been produced in limited amounts at the University of Southern California.
You may also be interested in...
CHF Solutions adds “CEO” to its president’s job title; Agilent VP of business development promoted to senior VP; Zimmer hires chief transformation officer; and more.
Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.
EU Business Round-Up: Galenica Boosted By Deals, Alliance's Sales Rise, And Beiersdorf Relaunches Wound Care
Latest EU business news: Galenica posts sales up in 2020 thanks to deals; Alliance Pharma's Consumer sales edge up despite COVID-19; and Beiersdorf is relaunching its wound care range with sustainability in mind.